Found 9 dm-translational-medicine-and-human-genetics trials
A listing of dm-translational-medicine-and-human-genetics medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Familial lecithin:cholesterol acyl transferase (LCAT) deficiency (FLD) is a rare, hereditary disease with no treatment. It is caused by mutations in the gene for LCAT, an enzyme that is made in the liver and plays a role in the body’s ability to process (“metabolize”) cholesterol. People with FLD have very …
The purpose of this study is to study how a new investigational drug called lucerastat works in research subjects. Taking part in a research study is different from getting regular medical care. The aim of regular care is to improve your health. The aim of a research study is to …
This study seeks enroll 390 adult males and females with Severe Hypertriglyceridemia and with fasting TG 500 mg/dL (5.65 mmol/L) that are over the age of 18. The primary objective is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting TG from Baseline.
This study aims to identify how useful polygenic and integrated risk is in both helping doctors to treat and manage their patients, and identifying people at risk of developing coronary artery disease. Targeted population is previously genotyped individuals in the PMBB. We will calculate an integrated risk score for coronary …
This is a 12-month, multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the safety and efficacy of daily subcutaneous metreleptin treatment in subjects with Familial Partial Lipodystrophy (FPLD). Subjects will be assigned to 1 of 3 groups depending on HbA1c and fasting TGs levels. Participants will complete 10 visits …
Requesting a reliance agreement with an external IRB. The purpose of this double-blind, placebo-controlled trial is to evaluate the safety and efficacy of treatment with plozasiran on the reduction of fasting serum TG from Baseline in subjects with severe hypertriglyceridemia who have fasting TG levels above 500 mg/dL (5.65 mmol/L).
Requesting a reliance agreement with an external IRB. The purpose of this open label extension trial is to evaluate the safety and tolerability of treatment with olezarsen in subjects with severe hypertriglyceridemia who have completed the ISIS 678354-CS5 or -CS6 study with an acceptable safety profile.
Requesting a reliance agreement with an external IRB. The purpose of this double-blind, placebo-controlled trial is to evaluate the safety and efficacy of treatment with plozasiran on the reduction of fasting serum TG from Baseline in subjects with Hypertriglyceridemia who have fasting TG levels between 150 mg/dL and 499 mg/dL.
Requesting a reliance agreement with an external IRB. The primary objective is to evaluate the efficacy of obicetrapib alone for 8 weeks as compared to obicetrapib in combination with Evolocumab for an additional 8 weeks after initial obicetrapib treatment on percent change of Lp(a) levels from Baseline in people with …
